BDI "Ellison Confirms Superior Efficacy of Inhaled Lung Cancer Treatment ILC Compared to Existing Therapies"

[Asia Economy Reporter Hyunseok Yoo] VIDI announced on the 16th that its subsidiary Ellison's developing ‘ILC (Inhalable Lipid-Conjugated Cisplatin)’, whose main component is ‘Cisplatin’, minimizes toxicity and has long-term therapeutic effects.

Cisplatin is an already proven effective anticancer drug, but it also affects normal tissues without cancer cells, causing unnecessary toxicity and has the disadvantage of low efficacy due to the small amount of drug reaching the lungs. ILC, being researched by Ellison, is an inhalation therapy directly delivered to the lungs, enabling sustained drug release compared to existing treatments, allowing for long-term therapy.

Since it is designed to encapsulate cisplatin within a lipid complex and supply the therapeutic substance to the lungs through ‘transfersomes’, the drug concentration is at least 10 times higher than intravenous cisplatin administration, with less impact on normal tissues, resulting in lower systemic toxicity.

Ellison already completed a Phase 2 clinical trial in 2017 related to ‘lung metastasis of bone cancer (osteosarcoma)’ for the purpose of delaying and preventing lung cancer recurrence. The trial results showed that among 19 patients, 13 had a significantly longer actual recurrence time than the expected recurrence time based on historical data, verifying the effectiveness in delaying and preventing recurrence. Considering that no therapeutic agents developed in the past 30 years have improved patient survival rates and about 35% of patients failed first-line therapy, the company explained that such efficacy is encouraging.

A VIDI official said, “The research results received from Ellison prove that ILC has dramatically overcome the limitations of cisplatin administration methods in the body,” adding, “ILC aims for commercialization as a treatment for lung cancer and osteosarcoma by 2026.”

He continued, “Since about 230,000 patients are expected annually in the United States alone for lung cancer, the U.S. market is estimated to reach 10 billion dollars,” and said, “We will actively pursue market entry following commercialization.”